×
About 945 results

ALLMedicine™ Factor XIII Center

Research & Reviews  356 results

Noninvasive prenatal diagnosis of congenital factor XIII deficiency in Iran.
https://doi.org/10.1097/MBC.0000000000001121
Blood Coagulation & Fibrinolysis : an International Journ... Motlagh H, Dorgalaleh A et. al.

Jan 5th, 2022 - Congenital factor (F) XIII deficiency is a rare coagulation factor deficiency that is inherited in an autosomal recessive manner. FXIII deficiency presents various clinical manifestations, such as intracranial hemorrhage (ICH), which is the most c...

Fibrin clot quality in acutely ill cirrhosis patients: relation with outcome and improv...
https://doi.org/10.1111/liv.15132
Liver International : Official Journal of the Internation... Blasi A, Patel VC et. al.

Dec 12th, 2021 - Patients with liver disease may acquire substantial changes in their hemostatic system, which are most pronounced in patients who are critically ill. Changes in the quality of the fibrin clot in critically ill patients have not been studied in det...

Cryptogenic oozers and bruisers.
https://doi.org/10.1182/hematology.2021000236
Hematology. American Society of Hematology. Education Pro... Smock KJ, Moser KA

Dec 11th, 2021 - Bleeding disorders with normal, borderline, or nondiagnostic coagulation tests represent a diagnostic challenge. Disorders of primary hemostasis can be further evaluated by additional platelet function testing modalities, platelet electron microsc...

First and fatal case of autoimmune acquired factor XIII/13 deficiency after COVID-19/SA...
https://doi.org/10.1002/ajh.26426
American Journal of Hematology; Shimoyama S, Kanisawa Y et. al.

Dec 3rd, 2021 - First and fatal case of autoimmune acquired factor XIII/13 deficiency after COVID-19/SARS-CoV-2 vaccination.|2021|Shimoyama S,Kanisawa Y,Ono K,Souri M,Ichinose A,|

An international collaborative study to assign value for Total Factor XIII-B Subunit An...
https://doi.org/10.1111/jth.15596
Journal of Thrombosis and Haemostasis : JTH; Raut S, Katona É et. al.

Nov 17th, 2021 - Factor XIII (FXIII)-B subunit measurements are required for the diagnosis and characterization of the type of FXIII deficiency. Furthermore, therapy for FXIII-A deficiency with recombinant FXIII (rFXIII-A) relies on available FXIII-B. To carry out...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  10 results

Embolism in COVID-19 Positive Patients
https://clinicaltrials.gov/ct2/show/NCT04910360

Jul 20th, 2021 - This study has conducted to find the possible links between genetic make up of ICU patients with severe Covid-19 and embolism. 13 polymorphisms and mutations that the investigators targeted are located on Factor II, Factor V, Factor XIII, MTHFR, a...

Hemostasis Profile in Patients With Severe Subarachnoid Hemorrhage
https://clinicaltrials.gov/ct2/show/NCT03745456

Dec 4th, 2018 - Patients with severe subarachnoid hemorrhage (SAH) present platelet and coagulation dysfunctions immediately after the stroke, at least two weeks after the onset of SAH. These alterations have been implicated in the presentation of delayed cerebra...

Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
https://clinicaltrials.gov/ct2/show/NCT03634215

Aug 16th, 2018 - Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot. It also minimizes fibrin degradation by its cross-linking it w...

Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
https://clinicaltrials.gov/ct2/show/NCT02568696

Mar 29th, 2018 - Background In clinical kidney transplantation organ retrieval, cold-preservation of the graft as well as restoration of the blood flow to the transplant cause tissue damage (ischemia/reperfusion injury). Clinically these events can manifest themse...

Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
https://clinicaltrials.gov/ct2/show/NCT02239146

Jan 11th, 2017 - This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate the safety of escalating single doses of rFXIII (recombinant factor XIII, catridecacog) administered following first time myocardial rev...

see more →

News  8 results

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

Whole genome sequencing benefits pediatric ICU patients
https://www.mdedge.com/chestphysician/article/195757/critical-care/whole-genome-sequencing-benefits-pediatric-icu-patients
Jim Kling, MDedge News

Mar 6th, 2019 - SAN DIEGO – In the pediatric intensive care unit (PICU), rapid whole genome sequencing (rWGS) with targeted phenotype analysis often leads to specific changes in patient management, similar to what is seen when rWGS is applied to neonatal ICUs. Th.

Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
https://www.mdedge.com/familymedicine/article/110923/bleeding-disorders/children-under-6-factor-xiii-deficiency-had-no
Hematology News; Neil Osterweil

Jul 28th, 2016 - ORLANDO –A recombinant form of factor XIII was effective at preventing serious bleeding episodes in young children with factor XIII-A subunit deficiency, a rare and serious bleeding disorder. In a small international phase III trial, there were no.

Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
https://www.mdedge.com/pediatrics/article/110923/bleeding-disorders/children-under-6-factor-xiii-deficiency-had-no-major
Neil Osterweil

Jul 28th, 2016 - ORLANDO –A recombinant form of factor XIII was effective at preventing serious bleeding episodes in young children with factor XIII-A subunit deficiency, a rare and serious bleeding disorder. In a small international phase III trial, there were no.

see more →